Pituitary and ovarian responses after an application of a low dose of the luteinizing hormone-releasing hormone (LHRH)-lytic peptide conjugate during the preovulatory period in ewes

Bret A. McLeod1†, William Hansel1†, Pawel M. Bartlewski1† and Genje Buenviaje1†

*Correspondence: pmbart@uoguelph.ca
†All authors contributed equally to this work.
1Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, ON, Canada.
2Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA, USA.

Abstract

The aim of this experiment was to determine the effects of a low dose (0.2 mg/kg body weight i.v.) of the luteinizing hormone-releasing hormone (LHRH)-lytic peptide conjugate (LHRH-Phor21) on the periovulatory ovarian and endocrine events, ensuing luteal function and fertility in an ovine experimental model. We hypothesized that the dense expression of LHRH receptors on the anterior pituitary and ovarian structures would make them highly susceptible to the membrane disrupting ability of LHRH-Phor21. Six sexually mature Rideau Arcott ewes were used to test the effects of the conjugate; seven ewes served as controls. Prior to drug administration, estrus was synchronized with intravaginal medroxyprogesterone acetate (MAP)-releasing sponges that were left in place for 12 days and a single i.m. injection of 750 IU of equine chorionic gonadotropin (eCG) given at sponge removal. LHRH-Phor21 or saline were administered 36 h after MAP sponge withdrawal/eCG injection, around the expected onset of the endogenous discharge of gonadotropins. Treatment resulted in greater (p<0.05) peak LH concentrations and an earlier rise (p<0.05) in estradiol secretion in LHRH-Phor21-treated than control ewes; however, there were no differences (p>0.05) in the mean number of ultrasonographically detected luteal structures and serum progesterone concentrations during the luteal phase post-treatment. There were no differences (p>0.05) in the number of ewes that lambed or lamb characteristics between the two groups at lambing 9 months post-treatment. Overall, there was no adverse effect of LHRH-Phor21 on the ovulatory process, luteal function and lamb productivity in the ewes of the present study. With a lack of suppressive effects of LHRH-Phor21 on the pituitary-ovarian axis and fertility, our results support the suitability of the drug as a potential cancer pharmaceutical in reproductive-aged women.

Keywords: Conjugated lytic peptide, luteinizing hormone-releasing hormone, ovulation, luteogenesis, antral follicle development, ewe, transrectal ultrasonography

Introduction

Luteinizing hormone-releasing hormone (LHRH), a decapeptide synthesized by the hypothalamic neurosecretory cells, is a key regulator of the development of reproductive tissues and gonadal function [1-8]. However, the overexpression of LHRH receptors found in reproductive tissue cancers such as breast, prostate, ovarian and endometrial cancer has been associated with the undesirable progression of the disease [9-17]. Although LHRH receptors are densely expressed on the anterior pituitary, earlier studies in rats have shown that after the treatment with maximum tolerated doses of LHRH cytotoxic analogs, the suppressive effect on gonadotropin secretion was transient and reversible [11]. LHRH receptors are also expressed on extraptuitive cells and tissues including lymphocytes, mammary gland, ovary, and prostate [7,8,10,18]. The extraptuitive LHRH receptors may represent an additional target for the lytic action of cell disrupting peptides conjugated with LHRH.

LHRH-lytic peptide conjugates act as molecular cytotoxic transporters carrying lytic peptides to tissues expressing complement receptors [9,15,19]. These synthetic conjugates are linear, positively charged, amphipathic and α-helical molecules. Although not completely understood, the proposed mechanism of action proceeds via disrupting the negatively charged cell membranes, creating microscopic pores that allow unregulated ionic flow across the membrane, which ultimately results in cell death [9,20]. The entire process is completed within minutes after the lytic peptide interacts with the membrane [9].

In the present study, we used the lytic peptide Phor-21 (21 amino acids) linked to LHRH (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2). This is a relatively new conjugate and so no studies have been done to evaluate the anti-cancer effects of this drug. However, previous studies using Phor21 conjugated to a fragment of the beta chain of humanchorionic gonadotropin (βCG) showed a significant decrease in tumor burden both in vitro and in vivo [9,21-23]. Phor21-βCG(ala) was demonstrated...
McLeod et al. Journal of Cancer Therapeutics and Research 2013, http://www.hoajonline.com/journals/pdf/2049-7962-2-4.pdf

to destroy human breast cancer xenografts in nude mice at much lower doses (0.2 mg/kg body weight) than other conjugated lytic peptides tested [9]. Another lytic peptide, hecate (23 amino acid), conjugated to LHRH was also shown to be very effective in suppressing the growth of cultured prostate cancer cells and human prostate cancer xenografts implanted in nude mice; in those studies, the growth arrest of tumor cells and marked reduction of tumor burden were observed [9,21-23]. However, LHRH-hecate was found to impair spermatogenesis and damage interstitial cells in the testes of nude mice bearing prostate cancer cell xenografts [24].

The effect of lytic peptide conjugates on tumor burden and the restoration of normal physiological function after cessation of treatment paved the way to further research into this modality of the targeted cancer therapy. Investigation of the effects of lytic peptide conjugates on LHRH-mediated processes such as ovulation and the formation of luteal structures in a non-rodent species is still required [25]. Sheep are widely used as a model for human reproductive processes because of their similarities in body size, hormonal profiles during ovulatory cycles and ovarian kinetics [25-27]. Hence, utilizing ewes as an experimental model, the aim of the present study was to evaluate the effect of LHRH-Phor21 on pituitary and ovarian function, and fertility post-treatment. We hypothesized that LHRH-Phor21 would bind to the LHRH receptors on the anterior pituitary and ovarian structures leading to a decreased gonadotropin release and ovarian follicular steroidogenesis. This decrease in reproductive hormone biosynthesis would then result in failure of follicle selection for ovulation or inadequate corpus luteum formation detected via ultrasound and hormone measurements.

Materials and Methods

All experimental procedures were in compliance with the Canadian Council on Animal Care guidelines and had been approved by the local Animal Care Committee. The experimental approaches used and drug dosing in the present study were based on the previously validated and published methodology [25]. Clinically healthy, sexually mature Rudge Arcott ewes (n=13) of similar age (mean±SEM: 3.2±0.3 years; range: 3 to 7 years) and weight (mean±SEM: 78.5±1.7 kg; range: 68 to 85 kg) were housed in the Ponsonby Animal Health, Belleville, ON, Canada) were injected i.m. with medroxyprogesterone acetate, MAP; 60 mg) were inserted intravaginally, 3.2±0.3 years; range: 3 to 7 years) and weight (mean±SEM: 78.5±1.7 kg; range: 68 to 85 kg) were housed in the Ponsonby Animal Health, Belleville, ON, Canada) were injected i.m. with medroxyprogesterone acetate, MAP; 60 mg) were inserted intravaginally.

Following this protocol, the ewes are in estrus ~48 h after sponge withdrawal and ovulate ~14 h later. LHRH-Phor21 (0.2 mg/kg body weight i.v.) was administered 36 h after sponge removal, just prior to the expected pre-ovulatory discharge of gonadotropic hormones. Blood samples were drawn every 2 h, from 24 to 60 h after sponge removal/eCG injection, and then twice daily (from 3 to 7 days after MAP sponge removal/eCG injection) and daily until the end of the 19-day period after estrus synchronization, as previously described [25]. All ewes underwent transrectal ovarian ultrasonography 3 days after drug/saline injection to visualize and count all luteal structures. Ewes were scanned with the high-resolution B-mode ultrasound echo camera (Aloka SSD-3500SD; Aloka Co., Tokyo, Japan) connected to a 7.5-MHz bi-plane linear probe [28,29]. Ovarian images were displayed on the viewing screen of an ultrasound scanner at 1.5x to 2x image magnification, using a linear-array component of the bi-plane probe. Digital images of both ovaries were captured and stored on a compatible DVD recorder (Pioneer® DVD Recorder DVR-510H, Pioneer Electronics of Canada Inc., Markham, ON, Canada) for analysis of ovarian images at a later date.

The serum samples were analyzed for levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol 17-β (E2) and progesterone (P4) [25]. The intra-assay coefficients of variation (CVs) for reference sera with mean LH concentrations of 0.44 or 2.33 ng/ml were 10.3% and 4.6% respectively. The intra-assay CVs for reference sera with mean FSH concentrations of 0.52 or 2.90 ng/ml were 4.8% and 3.0% respectively. The intra-assay CVs for reference sera with mean estradiol 17-β (E2) concentrations of 0.52 or 2.90 ng/ml were 4.8% and 3.0% respectively. The intra-assay CVs for reference sera with mean progesterone (P4) concentrations of 1.4 or 4.1 ng/ml were 9.4% and 5.5%, respectively.

A comparison of the single time-point observations obtained from LHRH-Phor21–treated ewes and control animals was done using Student t-test (SigmaStat® 2.0 for Windows®; SPSS Inc., Chicago, IL, USA). Two-way ANOVA was used to compare serum concentrations of gonadotropic and steroid hormones over time (from 36 to 60 h after sponge removal/eCG injection) and between treatment and control groups. Statistical significance was regarded as p<0.05. Fisher’s protected least significant difference (LSD) was used after ANOVA to test the differences between individual means. In addition, the time from treatment to peak concentration, the maximum concentration and the area under the curve (AUC) for serial concentrations were calculated for serial LH, FSH and estradiol-17β concentrations in individual ewes. AUC was calculated using NCSS Statistical Software (Kaysville, UT, USA; http://www.ncss.com). Data are expressed as mean±SEM.

Results

Three days following the injections in the treatment and control groups, luteal structures were detected with ultrasonography.
in all but one treated ewe. The total number of luteal structures per ewe (2.1±0.3) did not differ (p>0.05) between the two subsets of animals. The time elapsed from MAP sponge removal/eCG injection to the peak of estradiol-17β secretion was less in treated compared to control ewes (40.0±1.7 and 47.4±2.8 h, respectively; Table 1). The peak LH concentration was greater in LHRH-Phor21-treated than control ewes (18.08±3.60 and 9.24±3.40 ng/ml, respectively; Table 1). No other characteristics of the periovulatory secretion of LH, FSH and estradiol-17β differed between the two groups of ewes (p>0.05; Table 1 and Figure 1). There were no differences (p>0.05) in the mean daily progesterone concentrations between the two groups during the luteal phase post-treatment (Figure 2). Lastly, there were no differences (p>0.05) in the ovulation rate, the percentage of

Table 1. Pituitary and ovarian endocrine responses in LHRH-Phor21-treated (0.2 mg/kg body weight i.v.) and control ewes.

| Hormone/Group/Variable | Time to peak (h)* | Peak concentration** | AUC for serial hormone concentrations*** |
|------------------------|------------------|----------------------|----------------------------------------|
| LHRH-Phor21            |                  |                      |                                        |
| Control (saline)       | 44.8±5.1         | 9.24±3.40a           | 58.6±35.3                              |
| LHRH-Phor21 (n=6)      | 42.0±4.7         | 18.08±3.60b          | 126.5±51.1                             |
| FSH                    |                  |                      |                                        |
| Control (saline)       | 44.6±4.7         | 2.73±0.48            | 5.6±1.2                                |
| LHRH-Phor21 (n=6)      | 42.3±4.5         | 3.97±0.71            | 6.5±1.1                                |
| Estradiol-17β          |                  |                      |                                        |
| Control (saline)       | 47.4±2.8a        | 12.3±2.1             | 95.1±7.0                               |
| LHRH-Phor21 (n=6)      | 40.0±1.7b        | 11.7±1.4             | 103.6±15.7                             |

* Time from MAP sponge removal/PMSG injection to maximum hormone concentration
** LH and FSH (ng/ml) and estradiol-17β (pg/ml)
*** AUC-Area under the Curve (from 36 to 60 h after MAP sponge removal/eCG injection)
ab Within columns, means for each hormone denoted by different letters are different (p<0.05).
The purpose of this study was to determine the effect of a lytic peptide conjugate LHRH-Phor21 on the anterior pituitary function and dynamic ovarian processes (ovulation, luteogenesis and ensuing luteal function) in an ovine experimental model. We hypothesized that LHRH-Phor21 would target receptors on the anterior pituitary and ovary, transiently decreasing the LH release and affecting the LH-mediated ovarian processes, including ovulation and ovarian steroidogenesis. However, our results did not indicate a truncated LH release or a significant negative effect on terminal antral follicle development and luteogenesis. Alternatively, a moderate stimulatory effect of LHRH-Phor21 on the phasic release of LH and follicular estradiol was observed.

Conjugated lytic peptides were developed to target and suppress the proliferation of malignant tumor cells while leaving somatic cells unharmed. Their selectivity is not confined to the ligand-receptor interactions; the lytic peptides also exhibit a preference for binding to cell membranes with abundant negatively-charged phospholipids [9,20]. In their native and immune role, lytic peptides preferentially lyse bacterial cell membranes while sparing normal/healthy mammalian cells [12], this affinity is a result of negatively charged acidic phospholipids contained within bacterial cell membranes. Compelling evidence regarding the selectivity of conjugated lytic peptides for negatively charged membranes with elevated content of phosphatidylycerine groups in cancerous tissues was provided by a study comparing the lysing potential of conjugated lytic peptides on CHO (Chinese Hamster Ovary) cells transfected with luteinizing hormone/human chorionic gonadotropin (LH/hCG) receptors and hCG receptor-positive MDA-MB-435 S breast cancer cells; the conjugated lytic peptides were less effective at destroying the neutral CHO cells [12]. Those earlier results and our present observations may be interpreted to suggest that the cell surface charge is a determining factor for triggering lytic actions of the conjugated lytic peptides anchored to target cells by the hormone carriers.

Significant in the interpretation of our results may also be the consideration of the multiple types of GnRH molecules and, to some extent, of GnRH receptors. Although it is undisputed that the principal target and source for GnRH is the anterior pituitary and hypothalamus respectively, there is now significant documentation of extra-hypothalamic origin of LHRH as well as extra-pituitary LHRH receptors [26]. Furthermore, a second form of GnRH, GnRH-II, was first identified in the chicken brain and is structurally conserved in vertebrate species ranging from fish to humans [18,20,30,31]. Hence in mammals two forms of GnRH coexist: GnRH I that regulates gonadotropin secretion and GnRH II, a neuromodulator that mainly stimulates sexual behavior [32]. GnRHs can also be detected in normal reproductive tissues and the reproductive tissue tumors in which their paracrine and/or autocrine roles are postulated [32]. A unique feature of the GnRH receptor is the lack of a carboxy-terminal cytoplasmic tail, which is believed to be involved in desensitization and internalization of other G protein-coupled receptors [6]. In contrast to the type I receptors, the type II GnRH receptors expressed in reproductive tissues and in the central nervous system are rapidly internalized and also propagate a distinctly separate signaling pathway [6]. Interestingly, in man and some other mammalian species (e.g., chimp, sheep and bovine), the type II GnRH receptor has been evolutionary silenced [32]. This phylogenetic variation makes the sheep a suitable species for studying the effects of GnRH as a model for human beings. Nevertheless, GnRH I and GnRH II still appear to have distinctive roles in signalling differentially through the type I receptor and may produce dissimilar downstream effects. The increase in peak concentrations of LH and FSH during certain key intervals in the sheep of the present study may be attributable to GnRH-Phor21 targeting the non-internalized GnRH type I receptors in the posterior pituitary (GnRH I-like effects) but the specific actions of the conjugate exerted at the ovarian level and in non-gonadal segments of the reproductive tract remain to be elucidated.

The present results clearly indicate that the hormonal portion of the conjugated lytic peptide has the ability to bind to its receptor (type I GnRH receptor) and to stimulate typical hormone-dependent responses in healthy (non-cancerous) cells in vivo. It would now be imperative to examine if similar effects can be seen during the treatment of reproductive tissue cancers as stimulation of the endocrine function of gonads may be undesirable in patients undergoing cancer therapy. The systemic hormonal therapy involving administration of GnRH antagonists/superagonists, anti-estrogens and/or aromatase inhibitors is typically used to treat ovarian stromal and epithelial tumors [33,34]. However, a moderate increase in steroid and FSH production leading to increased synthesis and affinity of LH/hCG receptors may be beneficial in targeted

Discussion

\[\text{Table 2. Fertility results at lambing 9 months following the treatment of ewes with LHRH-Phor21 (0.2 mg/kg body weight i.v.) or saline (controls).} \]

| Group                  | Ewes lambing | No. of live births/ewe | Birth weight (kg) | Sex ratio (% male) | Related Information                                      |
|------------------------|--------------|------------------------|-------------------|-------------------|----------------------------------------------------------|
| Control (saline) (n=7) | 4/7          | 2.0±0.4                | 4.2±0.2           | 33.3±11.8         | -                                                        |
| LHRH-Phor21 (n=6)     | 4/6          | 2.5±0.6                | 3.8±0.2           | 20.8±12.5         | 1F stillborn + retained placenta (6 ml Procillin + 2.5 ml Anafen i.m.) |

Ewes that lambed or lamb characteristics between the treated and control ewes at lambing 9 months post-treatment (Table 2).

| Group                  | Ewes lambing | No. of live births/ewe | Birth weight (kg) | Sex ratio (% male) | Related Information                                      |
|------------------------|--------------|------------------------|-------------------|-------------------|----------------------------------------------------------|
| Control (saline) (n=7) | 4/7          | 2.0±0.4                | 4.2±0.2           | 33.3±11.8         | -                                                        |
| LHRH-Phor21 (n=6)     | 4/6          | 2.5±0.6                | 3.8±0.2           | 20.8±12.5         | 1F stillborn + retained placenta (6 ml Procillin + 2.5 ml Anafen i.m.) |

| Group                  | Ewes lambing | No. of live births/ewe | Birth weight (kg) | Sex ratio (% male) | Related Information                                      |
|------------------------|--------------|------------------------|-------------------|-------------------|----------------------------------------------------------|
| Control (saline) (n=7) | 4/7          | 2.0±0.4                | 4.2±0.2           | 33.3±11.8         | -                                                        |
| LHRH-Phor21 (n=6)     | 4/6          | 2.5±0.6                | 3.8±0.2           | 20.8±12.5         | 1F stillborn + retained placenta (6 ml Procillin + 2.5 ml Anafen i.m.) |

Discussion

The purpose of this study was to determine the effect of a lytic peptide conjugate LHRH-Phor21 on the anterior pituitary function and dynamic ovarian processes (ovulation, luteogenesis and ensuing luteal function) in an ovine experimental model. We hypothesized that LHRH-Phor21 would target receptors on the anterior pituitary and ovary, transiently decreasing the LH release and affecting the LH-mediated ovarian processes, including ovulation and ovarian steroidogenesis. However, our results did not indicate a truncated LH release or a significant negative effect on terminal antral follicle development and luteogenesis. Alternatively, a moderate stimulatory effect of LHRH-Phor21 on the phasic release of LH and follicular estradiol was observed.

Conjugated lytic peptides were developed to target and suppress the proliferation of malignant tumor cells while leaving somatic cells unharmed. Their selectivity is not confined to the ligand-receptor interactions; the lytic peptides also exhibit a preference for binding to cell membranes with abundant negatively-charged phospholipids [9,20]. In their native and immune role, lytic peptides preferentially lyse bacterial cell membranes while sparing normal/healthy mammalian cells [12], this affinity is a result of negatively charged acidic phospholipids contained within bacterial cell membranes. Compelling evidence regarding the selectivity of conjugated lytic peptides for negatively charged membranes with elevated content of phosphatidylycerine groups in cancerous tissues was provided by a study comparing the lysing potential of conjugated lytic peptides on CHO (Chinese Hamster Ovary) cells transfected with luteinizing hormone/human chorionic gonadotropin (LH/hCG) receptors and hCG receptor-positive MDA-MB-435 S breast cancer cells; the conjugated lytic peptides were less effective at destroying the neutral CHO cells [12]. Those earlier results and our present observations may be interpreted to suggest that the cell surface charge is a determining factor for triggering lytic actions of the conjugated lytic peptides anchored to target cells by the hormone carriers.

Significant in the interpretation of our results may also be the consideration of the multiple types of GnRH molecules and, to some extent, of GnRH receptors. Although it is undisputed that the principal target and source for GnRH is the anterior pituitary and hypothalamus respectively, there is now significant documentation of extra-hypothalamic origin of LHRH as well as extra-pituitary LHRH receptors [26]. Furthermore, a second form of GnRH, GnRH-II, was first identified in the chicken brain and is structurally conserved in vertebrate species ranging from fish to humans [18,20,30,31]. Hence in mammals two forms of GnRH coexist: GnRH I that regulates gonadotropin secretion and GnRH II, a neuromodulator that mainly stimulates sexual behavior [32]. GnRHs can also be detected in normal reproductive tissues and the reproductive tissue tumors in which their paracrine and/or autocrine roles are postulated [32]. A unique feature of the GnRH receptor is the lack of a carboxy-terminal cytoplasmic tail, which is believed to be involved in desensitization and internalization of other G protein-coupled receptors [6]. In contrast to the type I receptors, the type II GnRH receptors expressed in reproductive tissues and in the central nervous system are rapidly internalized and also propagate a distinctly separate signaling pathway [6]. Interestingly, in man and some other mammalian species (e.g., chimp, sheep and bovine), the type II GnRH receptor has been evolutionary silenced [32]. This phylogenetic variation makes the sheep a suitable species for studying the effects of GnRH as a model for human beings. Nevertheless, GnRH I and GnRH II still appear to have distinctive roles in signalling differentially through the type I receptor and may produce dissimilar downstream effects. The increase in peak concentrations of LH and FSH during certain key intervals in the sheep of the present study may be attributable to GnRH-Phor21 targeting the non-internalized GnRH type I receptors in the posterior pituitary (GnRH I-like effects) but the specific actions of the conjugate exerted at the ovarian level and in non-gonadal segments of the reproductive tract remain to be elucidated.

The present results clearly indicate that the hormonal portion of the conjugated lytic peptide has the ability to bind to its receptor (type I GnRH receptor) and to stimulate typical hormone-dependent responses in healthy (non-cancerous) cells in vivo. It would now be imperative to examine if similar effects can be seen during the treatment of reproductive tissue cancers as stimulation of the endocrine function of gonads may be undesirable in patients undergoing cancer therapy. The systemic hormonal therapy involving administration of GnRH antagonists/superagonists, anti-estrogens and/or aromatase inhibitors is typically used to treat ovarian stromal and epithelial tumors [33,34]. However, a moderate increase in steroid and FSH production leading to increased synthesis and affinity of LH/hCG receptors may be beneficial in targeted
cancer therapy using the lytic peptides conjugated with the βCG fragment [25]. Future studies should also address the effects of the LHRH-Phor21 peptide in males. In the course of prostate cancer, for example, hormone therapy may include the application of LHRH agonists, anti-androgens and the drugs that block adrenal steroidogenesis (ketoconazole and aminoglutethimide) [35]. Estrogens were used in the past to reduce testicular androgen production but because of the risk of serious side effects they are seldom used nowadays in the treatment of prostate cancer. Both androgens and estrogens are synthesized by testicular cells [36] and so the effects of the LHRH-lytic peptide conjugates on the pituitary function and gonadal steroidogenesis in males would be of interest.

Conclusion
Contrary to our expectations, there was no disrupting effect of a low dose of LHRH-Phor21 on the pituitary function and ovarian activity during the follicular phase of the ewes’ estrous cycle. Although our findings are generally supportive of the safety of LHRH-Phor21 as a cancer therapeutic in women of a reproductive age, the potential for individual variation, dissimilar cellular effects that GnRH mediates in different target cells/organs as well as a slight increase in gonadal steroidogenesis post-treatment warrant further studies.

Acknowledgement
This study was funded by the Natural Sciences and Engineering Research Council (NSERC) of Canada, and the Ontario Ministry of Agriculture, Food and Rural Affairs (OMAFRA). LHRH-Phor21 was provided by Esperance Pharmaceuticals Inc. We would also like to thank the staff at Ponsonby Research Station for the care and husbandry of experimental animals. The present results were presented, in the preliminary form, during the 44th Annual Meeting of the Society for the Study of Reproduction (Portland, OR, USA; July-August 2011).

Competing interests
The authors declare that they have no competing interests.

Publication history
Received: 21-Nov-2012 Revised: 24-Dec-2012 Accepted: 15-Jan-2013 Published: 25-Jan-2013

References
1. Bartlewski PM, Aravindakshan J, Beard AP, Nelson ML, Battista-Arteaga M, Cook SJ and Rawlings NC: Effects of medroxyprogesterone acetate (MAP) on ovarian antral follicle development, gonadotrophin secretion and response to ovulation induction with gonadotrophin-releasing hormone (GnRH) in seasonally anoestrous ewes. Anim Reprod Sci 2004, 81:63-75. | Article | PubMed
2. Bartlewski PM, Beard AP, Chapman CL, Nelson ML, Palmer B, Aravindakshan J, Cook SJ and Rawlings NC: Ovarian responses in gonadotrophin-releasing hormone-treated anoestrous ewes: follicular and endocrine correlates with luteal outcome. Reprod Fertil Dev 2001, 13:133-42. | Article | PubMed
3. Cheng CK and Leung PC: Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans. Endocr Rev 2005, 26:283-306. | Article | PubMed
4. Choi JH, Wong AS, Huang HF and Leung PC: Gonadotropins and ovarian cancer. Endocr Rev 2007, 28:440-61. | Article | PubMed
5. Kaiser UB, Conn PM and Chin WW: Studies of gonadotropin-releasing hormone (GnRH) action using GnRH receptor-expressing pituitary cell lines. Endocr Rev 1997, 18:46-70. | Article | PubMed
6. Millar RP: GnRHs and GnRH receptors. Anim Reprod Sci 2005, 88:5-28. | Article | PubMed
7. Neill JD, Musgrove LC and Duck LW: Newly recognized GnRH receptors: function and relative role. Trends Endocrinol Metab 2004, 15:383-92. | Article | PubMed
8. Ramakrishnappa N, Rajamahendran R, Lin YM and Leung PC: GnRH in non-hypothalamic reproductive tissues. Anim Reprod Sci 2005, 88:95-113. | Article | PubMed
9. Hansel W, Enright F and Leuschner C: Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo. Mol Cell Endocrinol 2007, 260-262:183-9. | Article | PubMed
10. Harrison GS, Wierman ME, Nett TM and Glode LM: Gonadotropin-releasing hormone and its receptor in normal and malignant cells. Endocr Relat Cancer 2004, 11:725-48. | Article | PubMed
11. Kovacs M, Schally AV, Nagy A, Koppan M and Groot K: Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A 1997, 94:1420-5. | Article | PubMed Abstract | PubMed Full Text
12. Leuschner C and Hansel W: Membrane disrupting lytic peptides for cancer treatments. Curr Pharm Des 2004, 10:2299-310. | Article | PubMed
13. Leuschner C and Hansel W: Targeting breast and prostate cancers through their hormone receptors. Biol Reprod 2005, 73:860-5. | Article | PubMed
14. Nagy A and Schally AV: Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers. Biol Reprod 2005, 73:851-9. | Article | PubMed
15. Reubi JC: Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003, 24:389-427. | Article | PubMed
16. Schally AV and Nagy A: Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 1999, 141:1-14. | Article | PubMed
17. Schally AV, Schally A: New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci 2003, 72:2305-2320. | Article | PubMed
18. White RB, Eisen JA, Kasten TL and Fernald RD: Second gene for gonadotropin-releasing hormone in human. Proc Natl Acad Sci U S A 1998, 95:305-9. | Article | PubMed Abstract | PubMed Full Text
19. Leuschner C, Enright FM, Gawronksa-Kozak B and Hansel W: Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors. Prostate 2003, 56:239-49. | Article | PubMed
20. Shai Y: Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim Biophys Acta 1999, 1462:55-70. | Article | PubMed
21. Gawronksa B, Leuschner C, Enright FM and Hansel W: Effects of a lytic peptide conjugated to beta HCG on ovarian cancer: studies in vitro and in vivo. Gynecol Oncol 2002, 85:45-52. | Article | PubMed
22. Hansel W, Leuschner C, Gawronksa B and Enright F: Targeted destruction of prostate cancer cells and xenografts by lytic peptide-betaLH conjugates. Reprod Biol 2001, 1:20-32. | Article | PubMed
23. Leuschner C, Enright FM, Melrose PA and Hansel W: Targeted destruction of androgen-sensitive and -insensitive prostate cancer cells and xenografts through luteinizing hormone receptors. Prostate 2001, 46:116-25. | Article | PubMed
24. Hansel W, Leuschner C and Enright F: Conjugates of lytic peptides and LHRH or betaCG target and cause necrosis of prostate cancers and metastases. Mol Cell Endocrinol 2007, 269:26-33. | Article | PubMed
25. Galloway EC, Hansel W and Bartlewski PM: The effects of a low therapeutic dose of betaCG fragment-lytic peptide conjugates on...
ovarian function and gonadotropin secretion in ewes: a randomized controlled trial. Reprod Biol 2010, 10:195-213. | PDF | PubMed

26. Barrett DM, Bartlewski PM, Batista-Arteaga M, Symington A and Rawlings NC: Ultrasound and endocrine evaluation of the ovarian response to a single dose of 500 IU of eCG following a 12-day treatment with progesterone-releasing intravaginal sponges in the breeding and nonbreeding seasons in ewes. Theriogenology 2004, 61:311-27. | Article | PubMed

27. Campbell BK, Souza C, Gong J, Webb R, Kendall N, Marsters P, Robinson G, Mitchell A, Telfer EE and Baird DT: Domestic ruminants as models for the elucidation of the mechanisms controlling ovarian follicle development in humans. Reprod Suppl 2003, 61:429-43. | Article | PubMed

28. Bartlewski PM, Beard AP and Rawlings NC: An ultrasonographic study of luteal function in breeds of sheep with different ovulation rates. Theriogenology 1999, 52:115-30. | Article | PubMed

29. Duggavathi R, Bartlewski PM, Pierson RA and Rawlings NC: Luteogenesis in cyclic ewes: echotextural, histological, and functional correlates. Biol Reprod 2003, 69:634-9. | Article | PubMed

30. Millar R, Lowe S, Conklin D, Pawson A, Maudsley S, Troskie B, Ott T, Millar M, Lincoln G, Sellar R, Sellar R, Faurholm B, Scobie G, Kuestner R, Terasawa E and Katz A: A novel mammalian receptor for the evolutionarily conserved type II GnRH. Proc Natl Acad Sci U S A 2001, 98:9636-41. | Article | PubMed Abstract | PubMed Full Text

31. Miyamoto K, Hasegawa Y, Nomura M, Igarashi M, Kangawa K, Matsuo H: Identification of the second gonadotropin-releasing hormone in chicken hypothalamus: evidence that gonadotropin secretion is probably controlled by two distinct gonadotropin-releasing hormones in avian species. Proc Natl Acad Sci U S A 1984, 81:3874-3878. | Article | PubMed Abstract | PubMed Full Text

32. Millar RP: GnRHs and GnRH receptors. Anim Reprod Sci 2005, 88:5-28. | Article | PubMed

33. Emons G, Ortmann O, Teichert HM, Fassl H, Lohrs U, Kullander S, Kauppila A, Ayalon D, Schally A and Oberheuser F: Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group. Cancer 1996, 78:1452-60. | PubMed

34. Makar AP: Hormone therapy in epithelial ovarian cancer. Endocr Relat Cancer 2000, 7:85-93. | Article | PubMed

35. Brawer MK: Hormonal therapy for prostate cancer. Rev Urol 2006, 8 Suppl 2:S35-47. | PubMed Abstract | PubMed Full Text

36. Carreau S, Bouraima-Lelong H, Delalande C: Estrogens: new players in spermatogenesis. Reprod Biol 2011, 11:174-193. | PubMed